Roche CEO Severin Schwan: Fueled By Innovation, Emerging Markets
Executive Summary
Roche’s CEO Severin Schwan says the Swiss group’s recent revamps, lack of patent expiries, and ongoing drug innovations give the world’s largest maker of cancer drugs a strong position to expand its sales globally, helped by new cutting-edge therapies and creative business approaches.
You may also be interested in...
Real World Data Solutions For Pharma’s Looming EBIT Crisis
The global pharmaceutical industry is facing decreasing margins triggered by various internal and external reasons. To address the crisis effectively long term, we see pharma’s integration into care management, combined with data generation and analysis of real-world outcomes, as a way to charge for the value pharma adds.
Roche Follow-On Development Strategy Highlighted By Strong 1H Results
Top oncology specialist Roche’s second quarter saw robust sales growth with new breast cancer medicines Perjeta and Kadcyla selling well, highlighting and further validating its strategy to develop follow-on drugs to replace or renew older treatments while expanding into new disease areas.
Isis Teams Up With Roche In Early-Stage Huntington’s Deal
The biotech’s latest tie-up is another validation of its technology that could help it garner further attention – and better economics – for some of its late-stage programs.